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ABSTRACT
Background: Cancer patients often report behavioral and cognitive changes following 
cancer treatment. These effects can be seen in patients who have not yet received treatment 
or have received only peripheral (non-brain) irradiation. Novel treatments combining 
radiotherapy (RT) and immunotherapy (IT) demonstrate remarkable efficacy with respect 
to tumor outcomes by enhancing the proinflammatory environment in the tumor. However, 
a proinflammatory environment in the brain mediates cognitive impairments in other 
neurological disorders and may affect brain function in cancer patients receiving these 
novel treatments. Currently, gaps exist as to whether these treatments impact the brain 
in individuals with or without tumors and with regard to the underlying mechanisms. 
Results: Combined treatment with precision RT and checkpoint inhibitor IT 
achieved control of tumor growth. However, BALB/c mice receiving combined treatment 
demonstrated changes in measures of anxiety levels, regardless of tumor status. 
C57BL/6J mice with tumors demonstrated increased anxiety, except following combined 
treatment. Object recognition memory was impaired in C57BL/6J mice without tumors 
following combined treatment. All mice with tumors showed impaired object recognition, 
except those treated with RT alone. Mice with tumors demonstrated impaired amygdala-
dependent cued fear memory, while maintaining hippocampus-dependent context fear 
memory. These behavioral alterations and cognitive impairments were accompanied by 
increased microglial activation in mice receiving immunotherapy alone or combined with 
RT. Finally, based on tumor status, there were significant changes in proinflammatory 
cytokines (IFN-γ, IL-6, IL-5, IL-2, IL-10) and a growth factor (FGF-basic). 
Materials and Methods: Here we test the hypothesis that IT combined with 
peripheral RT have detrimental behavioral and cognitive effects as a result of an 
enhanced proinflammatory environment in the brain. BALB/c mice with or without 
injected hind flank CT26 colorectal carcinoma or C57BL/6J mice with or without 
Lewis Lung carcinoma were used for all experiments. Checkpoint inhibitor IT, using 
an anti-CTLA-4 antibody, and precision CT-guided peripheral RT alone and combined 
were used to closely model clinical treatment. We assessed behavioral and cognitive 
performance and investigated the immune environment using immunohistochemistry 
and multiplex assays to analyze proinflammatory mediators.
Conclusions: Although combined treatment achieved tumor growth control, it 
affected the brain and induced changes in measures of anxiety, cognitive impairments, 
and neuroinflammation.
      Research Paper
Oncotarget9156www.impactjournals.com/oncotarget
INTRODUCTION
Behavioral and cognitive impairments are a 
common and devastating complication of cancer and 
cancer treatment [1–3]. These impairments often include 
difficulty concentrating, memory impairments, fatigue, 
and increased anxiety [4]. Cancer-related behavioral 
changes and cognitive impairments often last well beyond 
treatment, with up to 35% of patients reporting effects 
lasting months or years [5]. Given improved cancer 
outcomes and long-term survivorship, these impairments 
are becoming increasingly important to study. Cancer-
related neurological dysfunction, which may contribute to 
a suboptimal functional quality of life, has been widely 
reported in human patients, yet the underlying mechanisms 
remain elusive. 
Historically, these impairments have been associated 
with cytotoxic chemotherapy (“chemobrain”). However, 
these changes have also been identified in patients who 
have not yet received treatment or received peripheral 
(non-brain) radiation alone, demonstrating that these 
changes are most likely multifactorial [6–10]. One such 
factor that has come under recent scrutiny is the role of the 
immune system [11–15].
Neuroinflammation has been identified as a mediator 
of behavioral alterations and cognitive impairments in 
many neurological conditions, including Alzheimer’s 
Disease, Major Depression, and injury from cerebral 
ischemia [16–18]. The expression of key proinflammatory 
mediators such as TNFα, IL-1β, IFN-γ, and IL-6 have been 
associated with mood disorders and their administration 
has been shown to induce depressive symptoms [19]. 
In addition to enhanced expression of proinflammatory 
cytokines, increased microglial activation, especially in 
the limbic system, has been identified as an important 
contributor to neuroinflammation in Alzheimer’s disease, 
chronic stress, and depressed suicide victims [20–22]. 
Recent research supports the role of neuroinflammation in 
mediating the neurological dysfunction seen with cancer 
and cancer treatment [11, 14, 15, 23].
The role of immune activation in cancer-related 
neurological dysfunction becomes especially important 
when considering cancer therapies which rely in part or 
in total on activation of the immune system. The efficacy 
of radiation therapy, especially the abscopal response, is 
dependent in part on immune activation [24–27]. Direct 
radiation of the brain has been repeatedly associated with 
behavioral alterations and impairments in hippocampus-
dependent cognition and neurogenesis, effects which 
may be in part mediated by the immune system [28–32]. 
However, modeling neurological dysfunction following 
peripheral radiation in mice has only recently been 
explored [11]. 
In addition to radiation treatment, one of the 
most exciting developments in cancer therapeutics, 
immunotherapy, also relies on systemic immune activation. 
Immunotherapeutics have been developed based on 
findings that show that the immune environment in a tumor 
prior to treatment is associated with clinical outcomes in 
many cancers [33, 34]. An enhanced proinflammatory 
tumor environment is associated with increased survival 
following conventional cancer therapy, while anti-
inflammatory tumor profiles are associated with severely 
limited survival [33, 3 4]. Given that radiation therapy has 
also been implicated as an immune modulator, combined 
immunotherapy and radiation treatment provides an 
exciting synergistic possibility to initiate and amplify a 
beneficial anti-tumor response [16, 24, 35–37]. 
One immunotherapy demonstrating robust results in 
combination with radiation treatment involve antibodies 
against CTLA4 (anti-CTLA4), a checkpoint inhibitor. 
Anti-CTLA4 induces a proinflammatory environment 
characterized by increased immune infiltrates in the tumor 
and combines with radiation therapy to form protective 
immunity [36, 38]. Pre-treatment with anti-CTLA4 
antibodies before radiation therapy is optimal for tumor 
control in preclinical models [39] and is consistent with 
successful clinical anecdotes [40, 41] and a retrospective 
review [42]. Importantly, patients are currently 
being treated and experiencing sustained remissions 
with the combination of radiation therapy and anti-
CTLA4 immunotherapy [25, 40, 41]. These treatments 
demonstrate remarkable efficacy with respect to tumor 
outcomes. However, how these treatments may affect the 
immune environment in the brain, and behavioral and 
cognitive outcome measures, is unknown. As yet, very 
little is understood about the effects of these treatments 
on the brain, either in healthy individuals or in individuals 
with tumors, although fatigue has been reported [43, 44].
Clinical studies on cancer-related neurological 
dysfunction have been limited by the presence of 
numerous confounders, including genetic variability and 
related differences in immune function between patients. 
Mouse tumor models present a unique opportunity to study 
the consequences of cancer and cancer treatment on brain 
function in a controlled environment. Establishing a mouse 
model also allows studying behavioral and cognitive 
performance alongside tissue and molecular markers. 
The choice of a subcutaneous tumor model in multiple 
cell lines allows for precise and reliable comparison of all 
groups at each stage of tumor development, as compared 
to a spontaneous tumor model. Placement of the tumor 
on the hind flank also allows for the best understanding 
of immunological effects of peripheral radiation while 
avoiding direct damage to healthy tissues or vasculature 
that may otherwise confound results due to direct or 
indirect effects of vascular changes on CNS function [45].
The current study represents an approach to model 
cancer-related neurological dysfunction in two important 
ways. First, although previous models have examined the 
effects of tumor alone [46, 47], chemotherapy [48, 49], 
peripheral radiation in healthy mice [11], direct immune 
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stimulation [50, 51], and treatment of cancer-related 
neurological dysfunction [52, 53], none have examined 
the effects of peripheral radiation in tumor-bearing mice 
or of immunotherapy in any tumor state. This is not only 
pertinent to understand given the emerging potential of 
these therapeutics, but also for the particular insight they 
may give to the role of the immune system in general. 
This study includes both tumor-free and tumor-bearing 
mice, as well as examines the effects of radiation and 
immunotherapy both alone and combined (see Figure 1 for 
the experimental design). Second, this study involves the 
use of newly developed precision irradiation technologies 
and the use of distinct genetic backgrounds, which more 
closely models clinical relevance. The Small Animal 
Radiation Research Platform (SARRP) combines cone-
beam CT-guided imaging with precise radiation delivery 
and an automatically rotatable stage that allows for delivery 
of single or multiple beams of radiation to the tumor. This 
study models cancer-related cognitive dysfunction in two 
mouse models of cancer: BALB/c mice with colorectal 
carcinoma and C57BL/6J mice with lung carcinoma. 
The colon26 adenocarcinoma (CT26) and Lewis Lung 
carcinoma cell lines were chosen because they are known to 
secrete IL-6 and TNF-α, do not metastasize when injected 
subcutaneously, and have growth curves amenable to this 
experimental timeline [54, 55].
The primary objective of this study was to 
investigate how checkpoint inhibitor immunotherapy 
combined with radiation therapy will affect behavioral 
and cognitive performance in tumor-free and tumor-
bearing mice. Here, we show that the combination of 
radiation and immunotherapy enhances tumor control, 
but also affects behavioral and cognitive performance, 
as well as the inflammatory environment in the brain. 
Immunotherapy and radiation alone also seem to alter the 
immune environment in the brain, but do not cause the 
behavioral and cognitive changes seen with combined 
immunotherapy and radiation. Presence of tumor also 
affects behavioral and cognitive performance, and the 
immune environment in the brain. Collectively, these 
studies show that the neuroinflammatory, behavioral, and 
cognitive effects of radiation and immunotherapy must 
be closely considered in the context of cancer-related 
neurological dysfunction.
Figure 1: Control of tumor growth achieved with combined treatments. (A) Tumor visualization and isocenter placement 
using a cone-beam CT scan with 360 projections on the SARRP. (B) Delivery of 20 Gy focal radiation to the tumor site using a 10 × 10 mm 
collimator at a 50° angle to minimize dose to radiosensitive organs. (C) Growth of individual 3LL tumors in C57BL/6J mice on days 15 
to 28 in mice left untreated (NT), treated with radiation (RT) or immunotherapy (IT) alone, or combined treatment (CT). Tumor growth in 
mice receiving CT is significantly slowed compared to those receiving NT. Tumor growth in mice receiving RT or IT is not significantly 
different than NT. (D) Growth of individual CT26 tumors on days 15 to 28 in BABL/c mice in treatment groups described above. Tumor 
growth in mice receiving RT and CT is significantly decreased compared to NT.  *p < 0.05, ***p < 0.001 compared to NT, ANOVA, 
followed by Dunnett post-hoc (C, n = 10 per group; D, n = 5). 
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RESULTS
General health and motor function do not differ 
between groups
There were no apparent differences in phenotype 
between the experimental groups, aside from tumor 
growth in tumor-bearing groups. Initial body weights and 
body weights taken throughout Experiment 2 (Days 7, 
9, 11, 14, 18, and 25) showed no significant differences 
between groups or within groups across time (Table 1). 
All groups performed similarly with regard to exploratory 
activity in the open field and sensorimotor function on the 
Rotarod (Table 1). 
Tumor growth is only controlled in mice 
receiving radiation and immunotherapy
To evaluate the effects of radiation and/or 
immunotherapy on growth of 3LL lung carcinoma, tumor 
measurements (length and width accurately measured 
with calipers) were taken throughout Experiment 2 
(Days 7, 9, 11, 14, 17, 19, 21, 23, 25, and 28) and tumor 
areas calculated (Figure 1C). Only the combination of 
anti-CTLA4 checkpoint inhibitor immunotherapy with 
20 Gy focal irradiation to the tumor site (referred to as CT) 
produced a significant decrease in tumor areas as compared 
to no treatment (NT) (p < 0.05, repeated measures). No 
significant treatment effects were seen in groups treated 
with radiation (RT) or immunotherapy (IT) alone.
Decreased measures of anxiety following 
combined radiation and immunotherapy
Symptoms of anxiety and anxiety disorders are 
significantly more common in cancer patients than the 
general population [3, 56]. To assess levels of anxiety 
following radiation and immunotherapy, the number of 
entries into the center of the open field was analyzed in 
BALB/c with colorectal carcinoma (Figure 2A– 2B) and 
C57BL/6J with lung carcinoma (Figure 2C). Representative 
motion plots of open-field activity in Figure 2A show 
that BALB/c animals treated with combined radiation 
and immunotherapy crossed more frequently into the 
more-anxiety provoking center of the open field. This 
indicates decreased measures of anxiety in combination 
treated mice as compared to untreated mice (Figure 2B, 
p < 0.05, ANOVA). This effect was seen in both tumor-
free (TF) and tumor-bearing (TB) mice. However, in 
C57BL/6J mice, this decrease in measures of anxiety was 
only seen in tumor bearing mice (Figure 2C, p < 0.05, 
ANOVA with Dunnett post hoc). Tumor-bearing mice also 
showed higher measures of anxiety than tumor-free mice 
(p < 0.05, ANOVA). In fact, tumor-bearing mice receiving 
CT showed restored levels of anxiety on par with those of 
tumor-free mice receiving no treatment (p > 0.05, t test). 
Mice receiving either radiation or immunotherapy alone 
did not show any significant differences in measures of 
anxiety when compared to animals receiving no treatment. 
Other measures of behavior did not show effects of 
tumor or treatment. Behavioral despair was measured in 
Table 1: Body weights, motor function of C57BL/6 with or without 3LL tumors receiving no 
treatment, radiation alone, immunotherapy alone, or combined radiation and immunotherapy
Body weight Motor function







Open field  
velocity (cm/s)e
Tumor-free NT 19.36 ± 0.67 19.24 ± 0.54 1.34 ± 1.06 52.61 ± 4.82 5.98 ± 0.19
RT 20.72 ± 0.44 19.61 ± 0.58 0.84 ± 0.39 52.37 ± 5.15 5.37 ± 0.34
IT 21.00 ± 0.18 19.96 ± 0.72 1.20 ± 0.39 50.20 ± 4.53 5.47 ± 0.42
CT 19.58 ± 0.08 18.41 ± 0.82 0.96 ± 0.27 51.61 ± 5.22 5.28 ± 0.35
Tumor-bearing NT 18.62 ± 0.54 18.85 ± 0.42 1.98 ± 0.66 50.30 ± 4.46 5.50 ± 0.33
RT 19.86 ± 0.50 19.26 ± 0.51 1.32 ± 0.42 50.37 ± 5.26 5.38 ± 0.26
IT 19.90 ± 0.49 18.50 ± 1.11 0.76 ± 0.67 53.92 ± 3.84 5.19 ± 0.34
 CT 19.56 ± 0.53 19.28 ± 0.45 0.98 ± 0.62 55.30 ± 4.72 5.82 ± 0.34
Data expressed as mean ± SEM.
aValue given is mean initial body weight for animals in Experiment 2. (n = 5).
bValue given is mean body weight for animals in Experiment 2. (n = 4–5).
cWeight change was calculated as weight at the end of testing (day 25) minus weight at inoculation (day 0). (n = 4–5).
dRotarod latency to fall is the mean time to fall during each of 9 trials. (n = 10).
eOpen Field Velocity is the mean velocity (cm/s) over the course of three 5 minute exposures to the open field arena. (n = 10).
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Tumor-free NT 70.50 ± 3.52 43.85 ± 6.91 19.24 ± 0.54 265 ± 25.56
RT 71.67 ± 3.77 34.86 ± 9.31 19.61 ± 0.58 279.9 ± 36.1
IT 68.84 ± 5.38 26.80 ± 5.51 19.96 ± 0.72 271.6 ± 46.66
CT 68.89 ± 4.95 37.41 ± 9.39 18.41 ± 0.82 271.4 ± 26.11
Tumor-bearing NT 72.41 ± 4.20 61.15 ± 10.18 18.85 ± 0.42 266.5 ± 45.12
RT 58.83 ± 7.15 51.72 ± 10.78 19.26 ± 0.51 269.5 ± 48.08
IT 65.55 ± 2.75 42.98 ± 8.00 18.50 ± 1.11 267.2 ± 46.96
CT 69.33 ± 3.80 50.25 ± 6.34 19.28 ± 0.45 243.4 ± 26.17
Data expressed as mean ± SEM.
aPercent time immobile based on predominant behavior during 5s time-sampling for 300s. (n = 9–10).
bLatency to first immobility after placement in forced swim chamber. (n = 9–10).
cAverage nest score from three independent raters. (n = 9–10).
dAverage baseline motion (cm/s) during Fear Conditioning Training session. (n = 9–10).
Figure 2: Decreased measures of anxiety mice receiving combined treatment (CT) in two different mouse models of 
cancer. Number of entries into the center of the open field arena was used as a marker for anxiety behavior. (A) Representative tracks of 
open field behavior as recorded in BALB/c mice ± CT26 inoculation left untreated (NT) or treated with CT. (B) Both tumor-free (TF) and 
tumor-bearing (TB) BALB/c mice treated with CT demonstrate decreased measures of anxiety. (C) In C57BL/6J mice ± 3LL inoculation, 
measures of anxiety are increased in TB mice. However, TB mice treated with CT demonstrate decreased measures of anxiety. *p < 0.05 
compared to NT, ANOVA, followed by Dunnett post-hoc. #p < 0.05, ANOVA, effect of tumor. (B–C, n = 10 per group). 
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Experiment 2 by determining the percent time a mouse 
spent immobile using the forced swim test, during 
which a mouse is introduced into a water-filled cylinder 
from which it cannot escape. There were no significant 
effects of tumor or treatment in percent time immobile 
during the forced swim test (Table 2). However, tumor-
bearing mice demonstrated a significantly longer latency 
to first immobility (Table 2.) Nest building is a natural 
rodent behavior that can model disrupted activities of 
daily living in people with cognitive impairment [57]. 
Regardless of tumor status or treatment received, mice in 
Experiment 2 demonstrated similar nest building scores 
(Table 2). Home-cage activity levels were measured 
in Experiment 3 through the use of infrared home-cage 
activity sensors across a 28-day period of four intervals: 
baseline activity (days –7 to –1), tumor growth (days 0 to 
6), post-IT (days 7 to 13), and post-RT (days 14 to 21). 
There were no significant effects of tumor or treatment 
on mean activity levels in the light or dark throughout the 
duration of the experiment (data not shown). Comparing 
mice at the tumor-free, no treatment (TF-NT) stage with 
mice after three weeks of tumor growth either receiving 
no treatment (TB-NT) or combined treatment (TB-CT) 
also showed no effect of tumor or treatment on home-cage 
activity (Figure 3A). Mean activity patterns also showed 
no significant differences (Figure 3B). 
Combined radiation and immunotherapy induce 
cognitive impairments in some dimensions in 
otherwise healthy mice
Novel object recognition was used to assess 
cognitive function. Following three acclimation periods, 
mice were exposed to two identical objects and allowed to 
freely explore (Figure 4A). Twenty-four hours later, mice 
were re-introduced to one of the previous familiar objects 
and a novel object. Except for the combined treatment 
group, all tumor-free mice showed a robust preference for 
the novel object (TF-NT, TF-IT p < 0.01; TF-RT p < 0.05, 
t test). However, tumor-free mice receiving combined 
radiation and immunotherapy displayed impaired object 
recognition. Among tumor-bearing mice, only the group 
receiving RT demonstrated a preference for exploring the 
novel object (p < 0.01, t test) (Figure 4B). 
Associative memory was assessed by training 
mice to associate a conditioned stimulus (tone) with a 
mild foot shock (unconditioned stimulus). Trained mice 
demonstrate fear of the conditioned stimulus by freezing 
in place [58]. There were no baseline differences in 
motion between groups during training (Table 2). To test 
contextual memory, mice were exposed to an identical 
environment as that encountered during their training. 
There were no differences between any of the experimental 
groups (Figure 4C). To test cued memory, a Pavlovian-
type response heavily regulated by the amygdala, mice 
were placed in a novel environment and exposed to the 
conditioned tone. Before the tone, all groups exhibited 
similarly low levels of freezing in response to the novel 
context (Table 2). However, once the tone was played, mice 
with tumors demonstrated decreased freezing as compared 
to tumor-free mice (p < 0.05, ANOVA), demonstrating an 
impairment in cue-dependent fear memory (Figure 4D). 
Immunotherapy elicits enhanced 
neuroinflammation including activation of 
microglia, but not neuronal degeneration
Microglial activation has been associated with 
many neurodegenerative conditions, especially in the 
limbic system [20, 21]. CD68 was used as a marker of 
the presence of activated microglia in the cortex and 
three regions of the hippocampus (CA1, CA3, and 
dentate gyrus) in the BALB/c mice with colorectal 
carcinoma (Figure 5A) and C57BL/6J mice with lung 
carcinoma (Figure 5B– 5C). In BALB/c mice, there was 
increased activation of microglia in the cortex, CA1, and 
CA3 following combined treatment in tumor-free mice 
(p < 0.05 for cortex and CA1; p < 0.01 for CA3; ANOVA 
with Dunnett post-hoc test). However, a significant 
interaction between treatment and tumor status was 
seen when comparing tumor-free to tumor-bearing mice 
(p < 0.05 for dentate gyrus, p < 0.01 for cortex, CA1, and 
CA3; ANOVA). Tumor-bearing mice receiving combined 
treatment had microglial activation levels similar to that 
of the tumor-free control (Figure 5A). A similar pattern 
of microglial activation was seen in tumor-free C57BL/6J 
mice: there was a significant effect of treatment in the 
cortex (p < 0.01, ANOVA), CA1 (p <  0.01, ANOVA), 
CA3 (p < 0.05, ANOVA), and the dentate gyrus 
(p < 0.01, ANOVA). In the dentate gyrus, there was a 
significantly higher level of activated microglia in mice 
receiving combined treatment compared to no treatment 
(p < 0.01, ANOVA with Dunnett posthoc).  In the C57BL/6J 
mice, however, a different trend emerged in the tumor-
bearing mice than that seen in BALB/c mice. Here, there 
was a significant effect of treatment (Cortex, CA1, and DG 
p < 0.01; CA3 p < 0.05, ANOVA). As seen in the tumor-
free C57BL/6J mice, there was a significantly higher 
level of microglial activation in mice receiving combined 
treatment compared to mice receiving no treatment in the 
dentate gyrus (p < 0.05, ANOVA with Dunnett posthoc).
Neuroinflammation in the context of cancer and 
cancer-treatment is frequently characterized by changes 
in expression of proinflammatory cytokines such as 
IL- 1β, IFN-γ IL-6, and TNF-α [47, 51]. IFN-γ expression 
was decreased in tumor-bearing mice in the cortex 
(p < 0.05, ANOVA; Figure 6A). However, IFN-γ levels are 
increased in the cortex of tumor-bearing mice following 
immunotherapy alone or combined treatments (p < 0.05, 
ANOVA). Mice treated with RT show lower levels of IL-6 
in the cortex as compared to mice receiving NT (p < 0.05, 
ANOVA with Dunnett posthoc). IL-1β and TNF-α levels 
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in the cortex and hippocampus did not vary with tumor 
status or treatment (data not shown). To further evaluate 
the neuroinflammatory response seen with peripheral 
tumor and combined treatment, a number of other 
important proinflammatory cytokines, chemokines, and 
growth factors were assessed as well. Of these, IL-5, FGF-
Basic, and IL-2 showed significant differences between 
groups in expression in the cortex. IL-10 was differentially 
expressed in the hippocampus (Figure 6B). 
In order to study the effect of combined therapy on 
T-cell infiltration of the brain, the occurrence of CD3+ T-cells 
was assessed via immunohistochemistry. CD3+ T cells 
were not observed in brain tissue sections of any group.
Fluoro-Jade C is a marker of degenerating neurons. 
There was no Fluoro-Jade C staining in any group.
DISCUSSION
Behavioral changes and cognitive impairments 
commonly accompany cancer and cancer treatment and 
can have a major impact on patient quality of life [59]. 
These behavioral changes and cognitive impairments 
are most likely at least in part mediated by the immune 
environment in the brain [3, 19, 51, 53, 74]. Because 
immune activation is at the core of efficacy of critical 
cancer therapeutics like radiation and immunotherapy, it is 
essential to understand how these treatments may introduce 
or exacerbate behavioral changes and cognitive deficits. 
This is especially important given durable improvements 
in survivorship achieved by checkpoint inhibitor 
immunotherapy [44]. We hypothesized that combined 
treatment with checkpoint inhibitor immunotherapy and 
peripheral radiation treatment would exacerbate cancer-
related neurological dysfunction. In this study, a mouse 
model of cancer-related neurological dysfunction was used 
to determine the effects of immunotherapy and radiation 
treatment on behavioral and cognitive performance, and 
neuroinflammation in tumor-free and tumor-bearing mice. 
Here we report that although combined treatment achieves 
the best tumor control, it is accompanied by behavioral, 
cognitive, and neuroinflammatory changes. 
One novel finding in this study is the change in 
measures of anxiety elicited by combined treatment. 
Symptoms of anxiety and depression are significantly 
Figure 3: Activity levels do not change with tumor development or treatment with combined immunotherapy and 
radiation. (A) Mean activity count was calculated for the light and dark periods of two 48 hr intervals. The first interval was taken over 
experimental days -1 and -2 and show mean activity levels immediately before tumor inoculation (TF-NT = tumor-free, no treatment). The 
second interval was taken during the last two days of the experiment, days 20 and 21, and shows mean activity levels in tumor-bearing 
(TB) mice receiving either no treatment (TB-NT) or combined treatment (TB-CT). There were no significant differences between groups. 
(B) Mean activity patterns showing no significant differences between TB-NT and TB-CT mice during the final 84 hours of Experiment 3. 
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more common in cancer patients than in the general 
population [3, 56]. In our animal models, the effect of 
peripheral tumor alone on measures of anxiety depended 
on genetic background and tumor type. C57BL/6J mice 
with lung carcinoma displayed increased measures of 
anxiety compared to their healthy controls, reflecting 
clinical data. However, BALB/c mice with colorectal 
carcinoma demonstrated no increase in measures of 
anxiety when compared to healthy controls, a finding 
which reflects previous studies of behavioral performance 
in this tumor model [47]. The lack of increase in measures 
of anxiety in BALB/c mice might be due to their generally 
lower exploratory activity, making small increases in 
measures of anxiety as compared to control mice more 
difficult to detect. Although depression is a common 
finding in cancer-related neurological dysfunction, our 
models did not show differences in percent time spent 
immobile between groups on the forced swim test. 
Although tumor-bearing mice demonstrated shorter 
latency to first immobility, this measure is not typically 
analyzed as the first minute of this test is considered 
habituation [61, 62]. In future studies, we plan to include 
more measures of depression-like behavior, including 
those focused on anhedonia. 
Another important novel finding in this study is the 
cognitive impairment seen with the presence of a peripheral 
tumor and combined treatment. Deficits in cognitive 
performance, including impairments in executive function, 
are frequently reported symptoms in cancer survivors [63, 
64]. This cognitive injury has been identified in cancer 
patients who have not yet been treated [1, 65]. This clinical 
finding was reflected in our mouse model. We saw impaired 
performance in both a version of an object recognition test 
that is hippocampus-dependent and amygdala-dependent 
Figure 4: Combined treatment (CT) and presence of peripheral tumor impair memory. (A) Mice were given access to two 
identical objects on Day 1. 24 hours later, mice were reintroduced to one familiar object (F) and one novel object (N). Mice recognizing the 
novelty of the new object spent a greater percentage of their time exploring this object. (B) In tumor-free (TF) mice, object recognition was 
seen in every group except mice receiving combined treatments (CT). In tumor-bearing (TB) mice, object recognition was only restored in 
mice treated with radiation alone (RT). (C) No impairments are seen in a test of contextual fear memory. (D) TB mice show impaired cued 
fear memory as compared to TF mice. *p < 0.05, **p < 0.01, (B, n = 10 per group).
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cued fear memory in mice with tumors. Of the three 
treatment arms (radiation alone, immunotherapy alone, and 
combined treatment), mice with tumors receiving radiation 
alone demonstrated the greatest recovery of cognitive 
function following treatment. Interestingly, only combined 
treatment with radiation and immunotherapy caused 
impairment of object recognition in otherwise healthy mice. 
Clinical reports and animal studies indicate that combining 
radiation and immunotherapy can result in a particularly 
potent anti-tumor effect [41, 66, 67]. Unfortunately, this 
potent combination may also have particularly deleterious 
effects on behavioral and cognitive performance, as shown 
by the pronounced behavioral changes and cognitive 
deficits in this group. 
There appear to be tumor- or mouse strain- specific 
differences in the neurocognitive response to treatment. 
Figure 5: Increased presence of CD68+ activated microglia in the hippocampus and cortex following immunotherapy 
(IT) or combined treatments (CT). (A) Representative images of CD68 immunostaining in the dentate gyrus (DG) of C57BL/6J 
mice ± 3LL inoculation receiving no treatment (NT), radiation alone (RT), immunotherapy alone (IT), or combined treatments (CT). 
Quantification of CD68 immunostaining in the cortex and hippocampus (CA1, CA3, DG) of (B) BALB/c mice ± CT26 inoculation or (C) 
C57BL/6J mice ± 3LL inoculation receiving NT, RT, IT, or CT. *p < 0.05, **p < 0.01 effect of treatment, ANOVA, followed by Dunnett 
post hoc. ^p < 0.05, ^^p < 0.01 interaction, ANOVA, followed by Dunnett post hoc. (B-C, n = 6 per group).
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The effect of tumor is shown to vary between strains, but 
in both cases combined therapy decreased measures of 
anxiety. Notably, on some measures, there appears to be a 
differential effect of combination therapy based on tumor 
status. In the absence of a tumor, combination therapy 
increased measures of anxiety and microglial activation, 
depending on genetic background. This observation may 
have relevance to the very variable individual response 
to immunotherapy in patient populations as well as the 
variable emergence of toxicities. BALB/c and C57BL/6 
mice are prototypical Th2 and Th1 skewed mouse strains 
and can have distinct responses to T cell and inflammatory 
triggers. These results indicate the importance of including 
healthy mice in assessing the effects of combination 
therapy on the brain and may have implications for 
extended use of these therapies beyond the point of 
achieving clinical cure of disease.
Microglial activation appears consistently 
increased following treatment with checkpoint inhibitor 
immunotherapy, although it is not accompanied by 
neuronal injury. Neuroinflammation is a likely mediator 
of behavioral changes and cognitive impairments seen 
with cancer and cancer treatment [46, 64]. Increased 
microglial activation, especially when chronic, has been 
associated with neurodegenerative conditions [18]. In 
both tumor-free and tumor-bearing mice, there was a 
robust increase in microglial activation depending on 
the treatment arm. These differences are particularly 
striking in the hippocampus, which is similar to findings 
of neuroinflammation in chronic stress and depression 
[20, 22]. The majority of inflammatory cytokines, 
chemokines, and growth factors did not show differences 
between groups. We did, however, observe significant 
changes based on tumor status in inflammatory cytokines 
(IFN-γ, IL-6, IL-5, IL-2, IL-10) and a growth factor (FGF-
basic). IFN-γ is a critical inflammatory mediator produced 
by chronically activated macrophages [68]. Cortical levels 
of IFN-γ were decreased in tumor-bearing mice, but 
restored to control levels following combined treatment. 
Decreased expression of IL-5, an important regulator of 
microglia and infiltrating macrophages in the brain [69], 
was also identified in tumor-bearing mice and tumor-free 
mice receiving radiotherapy alone. Associations with 
IL-5 and cancer-related fatigue have previously been 
described clinically [70]. Tumor-free mice receiving 
only radiotherapy also demonstrated decreased cortical 
expression of IL-6, which has been widely recognized 
as one of the most important regulators of neuroimmune 
function and has been repeatedly associated with cancer-
related neurological dysfunction [15, 71–73]. Modulation 
of the hypothalamic-pituitary-adrenal (HPA) axis is a 
likely mechanism for cognitive and behavioral changes 
seen with IL-6 expression [74]. Dysregulation of the HPA 
axis is strongly linked to changes in emotional behaviors 
Figure 6: Effect of peripheral tumor, RT, IT, and CT on cytokine, chemokine, and growth factor levels in the cortex 
and hippocampus. (A) Changes in cortex expression of IFN-γ, IL-6, IL-5, FGF-Basic, and IL-2. Lewis lung carcinoma inoculation 
induced changes in IFN-γ, IL-5, and FGF-Basic (p < 0.05, ANOVA). There was an effect of interaction of tumor status and treatment on 
expression levels of FGF-Basic and IL-2 (p < 0.05 for FGF-Basic, p < 0.01 for IL-2; ANOVA). There was significantly higher expression 
of IFN-γ and FGF-Basic in tumor-bearing mice receiving immunotherapy (IT) or combined treatment (CT) compared to mice receiving no 
treatment (NT) (p < 0.05, ANOVA with Dunnett posthoc). There was significantly lower expression of IL-6 and IL-5 in tumor-free mice 
receiving radiation alone (RT) versus NT (p < 0.05, ANOVA with Dunnett posthoc). (B) Tumor-inoculation increased expression of IL-10 
in the hippocampus (p < 0.05, ANOVA). Mice receiving RT demonstrate lower levels of IL-10 in the hippocampus (p < 0.05, ANOVA with 
Dunnett posthoc).
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[75] and represents an important potential mechanistic 
explanation for the behavioral changes and cognitive 
impairments seen in this model. Interestingly, there was 
a tumor x treatment interaction for the expression of 
both FGF-basic and IL-2 in the cortex. FGF-basic, which 
increases with learning and can contribute to recovery from 
cognitive injury [76, 77], was decreased in tumor-bearing 
mice, except those receiving immunotherapy, either with 
or without radiation. IL-2, a hallmark of proinflammatory 
polarization [78], demonstrated a robust tumor x treatment 
interaction. IL-2 is a potent inducer of vasopressin release 
from the hypothalamus [79] and corticotropin-releasing 
factor (CRF) from the amygdala [80], demonstrating 
another link to dysregulation of the HPA axis in this model. 
Finally, IL-10, an important immune inhibitory factor [81], 
was increased in tumor-bearing mice, but decreased in the 
hippocampus of mice without tumors treated with radiation 
only. Taken together, the alterations in expression identified 
in cytokines and a growth factor point to a significant role 
of dysregulation of the HPA axis as a potential mechanistic 
explanation for behavioral and cognitive changes following 
neuroinflammation in this model.
In this study, central neuroinflammation was 
identified in association with peripheral radiation and 
checkpoint inhibitor immunotherapy. In future studies, it 
would be important to investigate downstream mediators 
of the effects of neuroinflammation on behavioral and 
cognitive performance. Previous studies have demonstrated 
the potential for immune modulation of neurogenesis, 
neurotransmitter metabolism, and the HPA axis as potential 
effectors of downstream  behavioral and cognitive changes 
[11, 20]. Future studies are warranted to investigate 
the causative role of neuroinflammation in mediating 
behavioral and cognitive effects through the use of anti-
inflammatory agents in this model.
In our model, no differences were seen in home cage 
activity level during the light or dark phases for mice with 
tumors, regardless of whether they received combined 
immunotherapy and radiation treatment or not. Although 
fatigue is another hallmark of cancer-related neurological 
dysfunction [82, 83], our finding is consistent with previous 
studies showing that home cage activity is stable in the 
presence of a peripheral tumor [46, 52]. This also correlates 
well with the relatively normal performance of mice with 
tumors and treated mice in tests of general locomotor 
function and exploratory behavior. These findings indicate 
that neither tumor growth nor immunotherapy and radiation 
treatment, under the experimental conditions used, cause 
dramatic changes in lethargy levels or obvious sickness 
behavior, as assessed by analyzing home cage activity. 
Likely, the identified impairments are the result of deficits 
in higher-level cognition and behavior. We recognize 
that it is possible that significant fatigue exists, but is 
not exhibited by changes in levels of home-cage activity. 
Future studies will utilize voluntary wheel running activity, 
which has demonstrated differences in fatigue levels in 
recent models of cancer-related neurological dysfunction 
[11, 46, 48, 52, 53]. 
Cancer-related neurological dysfunction is a 
common and devastating consequence of cancer and 
cancer-treatment. With improved survivorship and the 
emerging use of novel therapeutics that may contribute 
to these effects, prevention and treatment of these 
behavioral and cognitive impairments is paramount. A 
better understanding of the role of the immune system in 
mediating these effects will facilitate the development of 
treatments to mitigate these effects in the near future.
Developing a model for the behavioral and 
cognitive changes following immunotherapy and radiation 
treatment allows us to better understand existing clinical 
data, expand knowledge of mechanisms, and eventually 
develop much-needed therapeutics. Much of the existing 
research on cancer-related neurological dysfunction to 
date has taken place in breast cancer survivors. Our use 
of only female mice reflects the preponderance of human 
data available. Utilizing two genetic backgrounds and 
tumor types allowed us to examine some of the inter-
individual and inter-population differences that are often 
so significant in translational research projects. 
In summary, tumor status has a significant bearing 
on the behavioral and cognitive effects of treatments. 
Future efforts are warranted to determine how adjuvant 




The study is divided into three experiments (Figure 7). 
The goal of the first experiment was to explore potential 
neurological effects of combined immunotherapy and 
peripheral irradiation. The goals of the second experiment 
were twofold: to determine role of 1) immunotherapy 
and radiation individually and 2) variability introduced 
by differences in genetic background and tumor type on 
neurological effects of combination treatment. Experiment 
three was a longitudinal study aiming to examine changes 
in circadian rhythm and fatigue through tumor inoculation, 
treatment, and recovery. Mice in Experiments 1 and 2 were 
transferred from the Earle A. Chiles Research Institute 
(EACRI) to Oregon Health and Sciences University 
(OHSU) on experimental day 14. Mice in Experiment 3 
remained at EACRI. Throughout the project, logistics and 
environment were standardized to minimize variation.
Animals
Female two- to four-month-old wild-type BALB/c 
(Experiment 1) and C57BL/6J (Experiments 2 and 3) mice 
were purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA) and allowed to acclimate to their surroundings 
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for 7-10 d before experiments. The CT26 and 3LL tumors 
models are derived from female mice and therefore 
female mice were used by necessity. Female mice are 
also preferred due to sexual dimorphism in severity of 
phenotype in tumor-bearing mice: male mice demonstrate 
greater mortality and weight loss as well as excoriation 
of the tumor site [47, 84]. Experiments were performed 
with  CT26 colorectal carcinoma which is syngeneic to 
BALB/c mice and with 3LL lung adenocarcinoma which is 
syngeneic to C56BL/6 mice. These cancer cells are grown 
in culture and transplanted to immunocompetent syngeneic 
mice to generate mouse models of colorectal carcinoma 
and lung adenocarcinoma. Subcutaneous tumors permit 
accurate radiation targeting and accurate measurement of 
response without impeding mouse freedom of motion or 
function. Rooms were maintained at 21°C on a 12 h light/
dark cycle with lights on from 06:00 to 18:00. All testing 
was performed between 08:00 and 16:00 unless otherwise 
noted. Normal chow diet (PicoLab Rodent Diet 20, #5053; 
PMI Nutrition International, St. Louis, MO, USA) and tap 
water were available ad libitum. All procedures were in 
compliance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and with 
IACUC approval at the EACRI and OHSU.
Cell lines
The CT26 murine colorectal carcinoma [85] 
(Experiment 1) and the Lewis lung carcinoma (3LL) 
murine cell line [86] (Experiments 2 and 3) were obtained 
from the ATCC (Manassas, VA, USA). Stocks were within 
3 passages of the ATCC clones with in vitro expansion 
used to generate a bank of matched early passage cells 
for subsequent experiments. Cells were grown in RPMI-
1640 media supplemented with HEPES, non-essential 
amino acids, sodium pyruvate, glutamine, 10% FBS, 
penicillin and streptomycin. All cell lines tested negative 
for mycoplasma by ELISA. To initiate tumor growth, 
cells were subcutaneously injected into the right flanks 
on experimental Day 0 at a dosage of 5 × 105 of CT26 
(Experiment 1) or 3LL (Experiments 2 and 3) cells 
suspended in 100 µL PBS per animal. Tumor-free mice 
were injected with PBS alone using the same procedure. 
In experiments 1 and 2, half of mice were tumor-free 
Figure 7: Experimental design. (A) Experiment 1 involved four groups: 1) tumor-free (TF), no treatment (NT); 2) TF, combined 
treatment (CT); 3) tumor-bearing (TB), NT; 4) TB, CT. (B) Experiment 2 involved eight groups: 1) TF, NT; 2) TF, radiation alone (RT); 
3) TF, immunotherapy alone (IT); 4) TF, CT; 5) TB, NT; 6) TB, RT; 7) TB, IT; 8) TB, CT. (C) Experiment 3 involved three longitudinal 
groups: 1) TF, NT; 2) TB, NT; 3) TB, CT; with only groups 2 and 3 present at the end of the experiment.
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(TF) and half of mice were tumor-bearing (TB). In 
experiment 3, all mice received tumors.
Immunotherapy and radiation therapy
On experimental day 7, mice were injected 
intraperitoneally with either 250 µg Anti-CTLA4 antibody 
(Clone #9D9, BioXCell, West Lebanon, NH) dissolved in 
PBS or PBS alone. On experimental day 14, mice received 
precision peripheral-irradiation or sham-irradiation using 
the Small Animal Radiation Research Platform (SARRP, 
XStrahl, Gulmay Medical, Suwanee, GA). Using a 
cone-beam CT scan with 360 projections, the tumor was 
visualized and isocenter was placed within the tumor. 
A single tangent beam using a 5 × 5 mm collimator 
was utilized to deliver 20 Gy (Figure 2), as previously 
optimized for the CT26 tumor model [39]. In experiment 1, 
all mice received either sham treatment (NT) or combined 
treatments (CT; 4 groups total; n = 10 mice/group; 40 mice 
total). In experiment 2, mice received either NT, peripheral-
irradiation only (RT), anti-CTLA4 immunotherapy only 
(IT), or CT (8 groups total; n = 10 mice/group; 80 mice 
total). In experiment 3, mice received either NT or CT 
(2 final groups; n = 8 mice/group; 16 mice total).
Behavioral and cognitive testing
Mice in experiments 1 and 2 underwent behavioral 
and cognitive testing beginning on experimental day 
15. Mice were singly housed 24 hours prior to the first 
behavioral test to minimize the effects of social influences 
on behavior. As alterations in exploratory behavior and 
measures of anxiety might affect performance in cognitive 
tests, they were assessed as well. Behavioral testing was 
performed in order of increasing stress level [28]. All 
behavioral testing was performed by an observer blinded 
to treatment group. The sequence of behavioral testing 
was: the open field (n = 10 mice/group/experiment), 
Rotarod (n = 10 mice/group/experiment), novel object 
recognition (n = 10 mice/group/experiment), fear 
conditioning (n = 10 mice/group/experiment), and forced 
swim test (n = 10 mice/group for Experiment 2). 
Measures of anxiety and exploratory behavior 
(open field, days 15-17)
The open field consists of a brightly lit enclosure 
(40.6 x 40.6 cm) with a white plastic floor and clear 
Plexiglas walls (Kinder Scientific, Poway, CA). On three 
consecutive mornings, mice were allowed to explore the 
enclosure for 15 minutes. Movement and exploration were 
tracked and analyzed with video software from Noldus 
Information Technologies (Ethovision XT 7, Wageningen, 
The Netherlands). Distance moved and percent of time 
spent in the center of the enclosure were analyzed as 
outcome measures. Number of entries into the center of 
the enclosure, assessed according to a programmed zone 
map, was used as a measure of anxiety-like behavior [87]. 
After each assessment of open-field activity, the equipment 
was cleaned with 5% acetic acid to remove residual odors.
Coordination and sensorimotor function 
(Rotarod, days 15-17)
Mice were placed on an elevated rotating rod 
(diameter: 3cm, elevation: 45cm; Rotamex-5, Columbus 
Instruments, Columbus, OH, USA) initially rotating at 5.0 
RPM. The rod accelerated 1.0 RPM every 3 s. A line of 
photobeams beneath the rod recorded the latency to fall 
(s). For three consecutive afternoons, each mouse received 
three trials per day with no delay between trials.
Object novelty recognition (days 18-19)
The object novelty recognition test relies on rodents’ 
natural curiosity and propensity to orient their attention 
toward a novel stimulus and is sensitive to hippocampal 
injury [88]. On day 18, mice were placed into the open 
field enclosure, identical to as described above, except 
containing two identical objects (small orange hexagonal 
prisms) placed 15 cm from the adjacent walls and 10 
cm apart (Figure 5). The mice were allowed 10 min to 
explore objects. On day 19, one of the identical objects 
(“familiar”) was replaced with a novel object (small green 
triangular prism) of identical dimensions. Movement and 
exploration were tracked and analyzed for nose, body, and 
tail with Ethovision XT 7. Nose point location within the 
object zone was used to determine exploratory behavior. 
Object novelty recognition was determined by calculating 
the percent time spent exploring the novel object out of the 
time spent exploring the novel and familiar objects. 
Associative learning and memory (days 25-26)
In this task, mice learned to associate a conditioned 
stimulus (CS, e.g. the environmental context, or a discrete 
cue-tone) with a mild foot shock (unconditioned stimulus, 
US). CS-US pairings are preceded by a short habituation 
period, from which a baseline measure of locomotor 
activity and other behavior can be scored. Contextual fear 
conditioning is thought of as hippocampus and amygdala 
dependent, while fear conditioning to a cue is considered 
to be amygdala-dependent but hippocampus-independent 
[89, 90]. Post-exposure freezing, defined as somatomotor 
immobility with the exception of respiration, is considered 
a post-exposure fear response, and is a widely used 
indicator of conditioned fear [58]. Mice were trained and 
tested using a Med Associates mouse fear conditioning 
system (PMED-VFC-NIR-M, Med Associates, St. Albans, 
Vermont) utilizing Med Associates VideoFreeze automated 
scoring system. Mice were placed inside a brightly lit fear 
conditioning chamber (100 lux) and allowed to habituate 
for 90 s. The mice were then exposed to a 30 s (80dB) tone 
(cue) paired with a 2 s 0.7 mA foot shock administered at 
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118 s, co-terminating with the tone at 120 s. This series 
was repeated for a total of five times. Twenty four hours 
later, contextual associative memory was assessed during 
re-exposure to the training environment for 300 s. Three 
hours later, mice were exposed to a modified environment 
(scented with vanilla extract, novel floor texture covering 
shock-grid, and a black plastic triangular insert for the 
walls), allowed to habituate to it for 90 s, and exposed to 
the sound cue for a period of 180 s. Associative learning 
was measured as the percent time spent freezing in 
response to the contextual environment or tone. Motion 
during shock was measured to account for sensor-motor 
differences in response to the aversive stimulus.
Depression-like behavior (day 27)
The forced swim test is commonly used to assess 
depression-like behavior in animals. It assesses degree of 
learned helplessness or behavioral despair as determined by 
the scoring of active (swimming and climbing) versus passive 
(immobility) behaviors in an inescapable cylinder filled with 
water [91–93]. In this procedure, mice were placed in cylinders 
filled with water (24°C to a depth of 15 cm) for 6 minutes 
and recorded. For the last five minutes of the trial, mice were 
scored as either immobile or mobile every 5 s. The mice were 
considered immobile once three paws were immobile and the 
fourth paw exhibited only minimal movement. Behavioral 
despair was measured as percent time spent immobile. 
Activity monitoring and nest building
For home cage activity monitoring (Experiment 3), 
16 mice were monitored for activity levels using infrared 
home-cage activity sensors (Biobserve, St. Augustin, 
Germany). Mice were housed and acclimated to the 
home-cage environment for three days prior to beginning 
activity measurement. All 16 mice received 3LL tumor 
injections one week later. Eight mice were treated with 
the protocol described above (anti-CTLA4 on day 7, RT 
on day 14). Activity counts (beam breaks) were measured 
every second for four weeks and data were expressed as 
mean activity count per hour. Due to technical problems, 
data for days 4, 10-13, and 17 were lost. Nest building 
was measured in Experiments 1 and 2 using an established 
protocol [94]. Briefly, mice were individually housed in 
a clean cage and provided two pressed cotton squares 
(Ancare, Bellmore, NY, USA). Photos of the home cage 
were taken 48 h later and visually rated by three different 
blinded scorers on a 5-point nest rating scale.
Histological evaluation
For histological evaluation, 6 mice from each group 
from Experiments 1 and 2 were intracardially perfused 
on experimental day 28 with 20-mL phosphate-buffered 
saline (PBS) followed by 40mL 4% paraformaldehyde. 
Brains were removed, stored in 4% paraformaldehyde 
overnight, and then transferred to 30% sucrose. Fixed 
brains were coronally sectioned at 40 µm into five 
series using a cryostat (Microm HM505E, MICROM 
international GmbH, Walldorf, Germany).
CD-68, CD-3 immunohistochemistry
CD-68 is a selective marker of activated microglia 
[95]. Anti-CD3 antibodies can be used effectively as T cell 
markers as the CD3 protein complex is a defining feature 
of the T-cell lineage [96]. Coronal brain sections were 
processed for immunohistochemical detection of CD-
68 or CD-3. Sections were rinsed in PBS, incubated in 
5% normal goat serum and 0.3% Triton-X in PBS (PBS-
TX) for 90 min, rinsed again with PBS, and incubated in 
primary antisera (CD-68 rat monoclonal: 1:500, Abcam, 
ab53444, Eugene, OR, USA; CD-3 hamster monoclonal: 
1:50, BD Biosciences, 550277, San Jose, CA, USA) in 
5% normal goat serum and PBS-TX overnight at 21°C. 
Sections were then rinsed in PBS and incubated for 2 h in 
biotinylated goat-anti-rat antibody (for CD-68; 1:200; Life 
Technologies, Eugene, OR, USA) or goat-anti-hamster 
antibody (for CD-3; 1:200; Invitrogen, Carlsbad, CA, 
USA) in PBS-TX. Following rinses in PBS, sections were 
immediately mounted on slides and coverslipped 3 h later 
with Vectashield Antifade Mounting Medium with DAPI 
(Vector Laboratories, Burlingame, CA, USA).
Fluoro-Jade C staining
Fluoro-Jade C can be used to identify degenerating 
neurons, regardless of mechanism of injury [97]. Coronal 
brain sections were prepared for Fluoro-Jade C staining. 
The sections were mounted on slides and allowed to dry. 
Slides were immersed in 80% ethanol with 1% NaOH for 
5 min followed by a 2 min soak in 70% ethanol and 2 min 
soak in distilled water. The slides were then incubated in 
0.06% potassium permanganate for 15 min, followed by 
a 2 min soak in distilled water, and 30 min incubation in 
0.0001% Fluoro-Jade C working solution. The 0.0001% 
working solution of Fluoro-Jade C was prepared by adding 
10 mL of the stock Fluoro-Jade C solution (0.01%) to 
990mL of 0.1% acetic acid in distilled water [97]. The 
working solution was used within 2 h of preparation. 
The slides were then rinsed in distilled water and air 
dried overnight. The air dried slides were then cleared in 
xylene for 2 min two times before being coverslipped with 
Permount (VWR, Visalia, CA, USA). 
Cytokine bead assay
For cytokine bead assays, cortical and hippocampal 
tissues were collected from 4 mice per group from 
Experiment 2. 25-300 mg of tissue was homogenized in 
4.5µL of ice cold PBS containing cOmplete EDTA-free 
Protease Inhibitor Cocktail (Roche Diagnostics USA, 
Indianapolis, IN, USA) per mg of tissue. Homogenates 
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were then centrifuged at 13000 g for 15 min and 
supernatants were transferred and stored at –80°C until 
used. Cytokine levels in the supernatants were detected 
using a murine multiplex bead assay (ThermoFisher 
Scientific, Waltham, MA, USA) and read on a Luminex 
100 array reader. Cytokine concentrations for replicates of 
each tissue sample were calculated according to a standard 
curve. Tested proinflammatory markers included cytokines 
(GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12 (p40/p70), IL-13, IL-17, TNF-α), chemokines 
(IP-10, KC, MCP-1, MIG, MIP-1α), and growth factors 
(FGF-basic, VEGF).
Statistical analyses
Data are expressed as mean ± standard error. 
Multiple groups and/or multiple time points were analyzed 
using two-way ANOVAs followed by Dunnett or Tukey-
Kramer post hoc tests when appropriate using Graph 
Pad Prism software (San Diego, CA, USA), or repeated-
measures ANOVA using SPSS software (Chicago, IL, 
USA). Only two-tailed t-tests were used. In addition to 
effects of tumor and treatment, interactions between effects 
of tumor and treatment were also assessed. A probability 
value of less than 0.05 was considered significant.
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